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Stem Cell Transplantation in Hematologic Malignancies
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Lujia Dong,1 Tong Wu,2 Zhi-Yong Gao,1 Mei-Jie Zhang,3 Fangyu Kan,4
Stephen R. Spellman,4 Xi-You Tan,1 Yan-Li Zhao,2 Jing-Bo Wang,2 Dao-Pei Lu,1,2
David Miklos,5 Effie Petersdorf,6 Marcelo Fernandez-Vina,7 Stephanie J. Lee6Haploidentical hematopoietic cell transplantation (HCT) has been used to treat hematologic malignancies,
but it is unknown whether the procedure is more effective in adults or children. To address this
question, we analyzed patients aged 1 to 65 years old receiving myeloablative conditioning regimens
followed by family 2 to 3 antigen HLA-mismatched HCT and reported to the Center for International
Blood and Marrow Transplant Research (CIBMTR; n 5 137) or performed in Dao-Pei Hospital in China,
China (n 5 181). The Dao-Pei cohort had more acute and chronic graft-versus-host disease (GVHD),
less relapse, lower transplant-related mortality (TRM), and better leukemia-free survival (LFS) than the
CIBMTR cohort. Overall survival (OS) and outcomes were similar between adults and children. In the
CIBMTR cohort receiving ex vivo T cell depletion (TCD), adults had higher TRM (relative risk [RR] 2.71,
95% confidence interval [CI] 1.29-5.69, P 5 .008) and lower OS (RR 1.75, 95% CI 1.08-2.84, P 5 .023)
than children. In the CIBMTR subset that did not receive ex vivo TCD, relapse was lower in adults compared
to children (RR 0.24, 95% CI 0.07-0.80, P 5 .020), but TRM, LFS, and OS were similar. We conclude that
outcomes in adults and children are similar overall, although children have better survival than adults if
ex vivo TCD is used.
Biol Blood Marrow Transplant 17: 1205-1213 (2011)  2011 American Society for Blood and Marrow TransplantationKEY WORDS: HLA-mismatched, Haploidentical, Blood and marrow transplantation, Leukemia, Antithymo-
cyte globulinINTRODUCTION
Family human leukocyte antigen (HLA)-
mismatched/haploidentical hematopoietic cell trans-
plantation (HCT) has been used as an alternative donor
source in patients who lack an appropriate HLA-1Fu Dan University Institute of Hematology, BMT Cen-
ao-Pei Hospital, Shanghai, People’s Republic of China;
Pei Hospital, Beijing, People’s Republic of China;
TR, Medical College of Wisconsin, Milwaukee, Wis-
; 4National Marrow Donor Program, Minneapolis, Min-
; 5Stanford University, Stanford, California; 6Fred
inson Cancer Research Center, Seattle, Washington;
.D. Anderson Cancer Center, Houston, Texas.
isclosure: See Acknowledgments on page 1212.
dence and reprint requests: Lujia Dong, MD, Fu Dan
rsity Institute of Hematology, BMT Center, No. 126
Road, Minhang County, Shanghai 200240, P.R. China
il: lujialidong@yahoo.com.cn).
uly 31, 2010; accepted December 16, 2010
erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2010.12.703matched related or unrelated donor for 30 years since
the first clinical trial was performed in 1980 [1,2]. The
advantages of family donors, even if partially
mismatched, are: (1) family donors are better matched
on shared complete haplotypes, including tested and
untested HLA and minor histocompatibility loci; (2)
almost all patients have at least 1 haploidentical donor
readily available, a particular advantage for patients
with advanced/resistant disease who need urgent HCT;
and (3) recent reports suggest that haploidentical HCT
can achieve nearly comparable therapeutic effects as
HLA matched sibling transplantation [3-5] and may
induce more potent graft-versus-tumor effect [6-9].
Most articles have reported the results of haploidentical
transplantation separately in adults [10,11] and in
children [12-15] or combined them into single reports
without comparing the 2 age groups. The goal of this
study was to investigate whether the outcome of
haploidentical HCT differs in adults and children, and
to identify the patient or transplant characteristics that
favor positive outcomes and survival in children and
adults undergoing haploidentical HCT.1205
Table 1. Patients, Disease, Transplant Characteristics
CIBMTR Cohort Dao-Pei Cohort
Characteristic of Patients Children1 n (%) Adults2 n (%) Children3 n (%) Adults4 n (%) P Value1 vs 2 P value3 vs 4 P Value1 vs 3 P Value2 vs 4
Number of patients 50 87 68 113
Number of transplant centers 25 32 1 1
Age, years
Median (range) 9 (<1-20) 35 (21-65) 15 (3-20) 33 (21-50) <.001 .021
0-10 years 27 (54) 0 11 (16) 0 — — <.001 <.001
11-20 years 23 (46) 0 57 (84) 0
21-30 years 0 32 (37) 0 45 (40)
31-40 years 0 24 (28) 0 46 (41)
41-50 years 0 16 (18) 0 22 (19)
51-60 years 0 12 (14) 0 0
Over 60 years 0 3 (3) 0 0
Sex, male 24 (48) 50 (57) 46 (68) 74 (65) .284 .766 .032 .247
Karnofsky prior to transplant .012 .046 .853 .073
<90 11 (22) 39 (45) 14 (21) 39 (35)
$90 39 (78) 46 (53) 54 (79) 74 (65)
Unknown 0 2 (2) 0 0
Disease .012 <.001 .280 <.001
Acute myeloid leukemia 19 (38) 53 (61) 17 (25) 39 (35)
Acute lymphoid leukemia 24 (48) 19 (22) 38 (56) 26 (23)
Chronic myeloid leukemia 5 (10) 8 (9) 12 (18) 38 (34)
Myelodysplastic syndrome 2 (4) 7 (8) 1 (1) 10 (9)
Disease status* .013 .009 .024 <.001
Early 12 (24) 24 (28) 29 (43) 58 (51)
Intermediate 19 (38) 14 (16) 27 (40) 22 (19)
Advanced 19 (38) 49 (56) 12 (18) 33 (29)
Time from diagnosis to transplant, months
Median (range) 9 (3-149) 9 (2-156) 7 (2-90) 8 (3-216) .260 .870 .389 .789
#12 months 29 (58) 58 (67) 52 (76) 86 (76) .310 .956 .033 .141
>12 months 21 (42) 29 (33) 16 (24) 27 (24)
Graft type .019 .047 <.001 <.001
BM 16 (32) 13 (15) 4 (6) 1 (1)
PB ± BM† 34 (68) 74 (85) 64 (94) 112 (99)
Use of ATG in conditioning or GVHD
prophylaxis
.617 — <.001 <.001
No 17 (34) 26 (30) 0 0
Yes 33 (66) 61 (70) 68(100) 113 (100)
Conditioning regimen .018 — <.001 <.001
TBI >500 cGY-single fraction or TBI
>800 cGY-fractionated ± others
25 (50) 20 (23) 0 0
Busulfan + cyclophosphamide + ATG ±
others
3 (6) 9 (10) 68 (100) 113 (100)
Busulfan + cyclophosphamide (no ATG) ±
others
6 (12) 7 (8) 0 0
TBI $500 cGY-single fraction or TBI
$800 cGY-fractionated ± others
11 (22) 38 (44) 0 0
Melphalan >150 mg/m2 ± others 0 3 (3) 0 0
Busulfan >9 mg/kg ± others 5 (10) 8 (9) 0 0
Busulfan + melphalan ± others 0 2 (2) 0 0
GVHD prophylaxis .075 — <.001 <.001
T cell depletion , ex vivo 35 (70) 55 (63) 0 0
Cyclosporine + methotrexate ± others‡ 11 (22) 17 (20) 68 (100) 113 (100)
Cyclosporine ± others (no methotrexate) 3 (6) 4 (5) 0 0
Methotrexate ± others (no cyclosporine) 1 (2) 0 0 0
Tacrolimus ± other 0 11 (13) 0 0
T cell depletion ex vivo .421 — <.001 <.001
No 15 (30) 32 (37) 68 (100) 113 (100)
Yes 35 (70) 55 (63) 0 0
Donor relationship <.001 <.001 .004 .106
Sibling, not identical twin 9 (18) 34 (39) 1 (1) 52 (46)
Parent of recipient 38 (76) 27 (31) 65 (96) 43 (38)
Child of recipient 0 21 (24) 0 16 (14)
Other relative§ 3 (6) 5 (6) 2 (3) 2 (2)
HLA matchingt — .954 — —
3/6 — — 34 (50) 57 (50)
4/6 — — 34 (50) 56 (50)
Sex match .704 .188 .029 .323
Donor male/recipient male 14 (28) 31 (36) 15 (22) 36 (32)
Donor male/recipient female 12 (24) 19 (22) 8 (12) 21 (19)
Donor female/recipient male 10 (20) 19 (22) 31 (46) 38 (34)
Donor female/recipient female 14 (28) 18 (21) 14 (21) 18 (16)
ABO match .637 0.826 0.474 0.049
Matched 33 (66) 59 (68) 35 (51) 58 (51)
Minor mismatch 8 (16) 8 (9) 16 (24) 21 (19)
Major mismatch 7 (14) 14 (16) 13 (19) 26 (23)
Bidirectional 2 (4) 4 (5) 4 (6) 8 (7)
Unknown 0 2 (2) 0 0
Donor age, years
Median (range)
37 (<1-53) 35 (10-72) 40 (16-55) 41 (13-66) .260 .359 .005 .152
(Continued )
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Table 1. (Continued )
CIBMTR Cohort Dao-Pei Cohort
Characteristic of Patients Children1 n (%) Adults2 n (%) Children3 n (%) Adults4 n (%) P Value1 vs 2 P value3 vs 4 P Value1 vs 3 P Value2 vs 4
#30 years 13 (27) 31 (36) 7 (10) 28 (25) .012 .001 .065 .121
31-40 years 23 (47) 17 (20) 34 (50) 28 (25)
$41 years 13 (27) 37 (44) 27 (40) 57 (50)
Unknown 1 (2) 2 (2) 0 0
Year of transplant .296 .407 <.001 <.001
2000-2003 39 (78) 74 (85) 20 (29) 40 (35)
2004-2005 11 (22) 13 (15) 48 (71) 73 (65)
Median follow-up of survivors, months (range) 40 (3-71) 38 (3-74) 49 (33-72) 47 (19-75) — — — —
BM indicates bone marrow; PB, peripheral blood; ATG, antithymocyte globulin; GVHD, graft-versus-host disease; TBI, total body irradiation.
*Early is defined as CR1, CP1, RA, RARS, treat without intent CR; intermediate is defined as $CR2, $CP2, AP; and advanced is defined as primary
induction failure, relapse, blast phase, refractory anemia excess blasts, refractory anemia excess blasts in transformation, CR not achieved.
†In CIBMTR data, PB + BM in children’s group n5 1; PB + BM in adults’ group n5 3. In Dao-Pei data, in children’s group BM+PB n564; in adults’ group
BM + PB n 5 109.
‡All Dao-Pei data were under cyclosporine + methotrexate + mycophenolate mofetil + ATG.
§Other relatives in CIBMTR data were: for children’s group, cousin n5 1; uncle n5 1; half-sib n5 1; for adults’ group, cousin n55. Other relatives in
Dao-Pei data were: for children’s group, cousin n 5 2; for adults’ group, cousin n 5 2.
tHLA matching is based on HLA-A, -B, -DRB1 low resolution.
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Patients
Patients with the diagnosis of acute lymphoblastic
leukemia (ALL), acute myelogenous leukemia (AML),
chronic myloid leukemia (CML), or myelodysplastic
syndrome (MDS), receiving myeloablative condition-
ing regimens with 2 to 3 antigen HLA-mismatched
family member donors between 2000 and 2005 were
included (Table 1). Adults were age 21 years or older,
and children were younger than 21 years old at the
time of HCT. A total of 137 patients (50 children, 87
adults) were reported to Center for International
Blood and Marrow Transplant Research (CIBMTR),
and 181 patients (68 children, 113 adults) were from
Dao-Pei Hospital in China.
CIBMTR Cohort
The CIBMTR is a research affiliation of the Inter-
national Bone Marrow Transplant Registry (IBMTR),
Autologous Blood and Marrow Transplant Registry
(ABMTR), and the National Marrow Donor Program
(NMDP) established in 2004 that comprises a volun-
tary working group of more than 450 transplantation
centers worldwide that contribute detailed data on
consecutive allogeneic and autologous HCT to a Sta-
tistical Center at the Medical College of Wisconsin in
Milwaukee and the NMDP Coordinating Center in
Minneapolis. Participating centers are required to re-
port all transplants consecutively; compliance is
monitored by on-site audits. Patients are followed
longitudinally, with yearly follow-up. Computerized
checks for discrepancies, physicians’ review of submit-
ted data, and on‑site audits of participating centers en-
sure data quality. Observational studies conducted by
the CIBMTR are performed in compliance with the
Privacy Rule (HIPAA) as a Public Health Authority,
and in compliance with all applicable federal regula-tions pertaining to the protection of human research
participants as determined by continuous review of
the institutional review boards (IRBs) of the National
Marrow Donor Program and the Medical College of
Wisconsin since 1985. Donor-recipient histocompati-
bility was determined by results of serologic typing
for HLA-A, -B, and -DR antigens as reported by
institutions performing the transplants. A variety of
conditioning and graft-versus-host disease (GVHD)
prophylaxis regimens were used (Table 1).Dao-Pei Cohort
All patients were treated on the same protocols ap-
proved by the IRB at Dao-Pei Hospital in China, and
all patients or their guardians signed consent forms.
HLA typing has been described previously [2,15].
Family members were tested for HLA compatibility
using serology and intermediate-resolution DNA
typing for HLA-A, -B, and -C antigens and high-
resolution DNA typing for HLA-DRB1 antigens.
Conditioning regimens and GVHD prophylaxis
have been described previously [3,16,17]. Briefly,
patients received combinations of cytarabine, oral
busulfan, cyclophosphamide, and methyl CCNU
prior to graft infusion. GVHD prophylaxis consisted
of antithymocute globulin (ATG), cyclosporine,
methotrexate, and mycophenolate mofetil. Approxi-
mately half of the patients in the current report were
also reported in the Lu et al. [3] 2006 Blood paper,
but the length of follow-up is significantly longer in
the present study (4 years versus 1.2 years).Endpoints
Absolute neutrophil count (ANC) recovery was
defined as blood ANC to$0.5  109/L on 3 consecu-
tive days. Platelet recovery was defined as the time after
transplantation needed to maintain a platelet count
1208 Biol Blood Marrow Transplant 17:1205-1213, 2011L. Dong et al.$20  109/L without transfusion support for 7 con-
secutive days. The acute GVHD (aGVHD) endpoint
referred to the development of grades 2-4 and grades
3-4 according to the Glucksberg criteria [18]. Chronic
GVHD (cGVHD) was diagnosed according to Seattle
definitions [19]. Transplant-related mortality (TRM)
was defined as death resulting from causes other than
relapse. Leukemia-free survival (LFS) was defined as
survival without recurrent malignancy.Statistical Analysis
CIBMTR and Dao-Pei data were analyzed sepa-
rately because of differences in patient and transplant
characteristics and major outcomes. Clinical variables
considered for inclusion in the models included: recip-
ient age and sex, Karnofsky performance score at
transplant, diagnosis, disease stage, time from diagno-
sis to transplant, stem cell source, ex vivo T cell deple-
tion, use of ATG in the conditioning regimen or
GVHD prophylaxis, donor relationship, number of
antigen incompatibilities, donor/recipient gender
match, ABO matching, donor age, and year of trans-
plantation. Cumulative incidence of neutrophil recov-
ery, aGVHD and cGVHD, TRM, and relapse were
calculated to accommodate competing risks. Probabil-
ities of survival and LFS were calculated using the
Kaplan-Meier estimate. Patients were not censored
for second transplant or donor leukocyte infusion
(DLI) for the endpoints of TRM, relapse, DFS, or
overall survival (OS). The log-rank test was used for
univariate comparisons.
Cox proportional hazards regression models were
applied for TRM, relapse, LFS, and overall mortality
using time-dependent covariates when appropriate.
The proportional hazard assumption was assessed for
each variable. Stepwise forward-backward selection
was used to build the models from the prognostic vari-
ables under consideration. The main effect of adults
versus children was kept in all models, and significant
other variables with P\ .05 were retained. SAS soft-
ware version 9.1 (SAS Institute, Cary, NC) was used.RESULTS
Patient, Disease, and Transplant Characteristics
The patient and transplant characteristics are
shown in Table 1. Comparing baseline characteristics,
the CIBMTR cohort differed from theDao-Pei cohort
in that the adults were older (P 5 .021), more patients
were in advanced stage for both children and adults
(P 5 .024 and P\ .001 respectively), more pediatric
patients waited longer than 12months before receiving
a transplantation (P 5 .033), more patients had trans-
plantation in the earlier time period (during 2000 to
2003) (P\ .001), and there were more cases of AMLand fewer CML cases in the adult group. All Dao-
Pei patients received ATG without ex vivo T cell de-
pletion (TCD), whereas 70% children and 63% adult
patients in the CIBMTR cohort had ex vivo TCD. A
total of 32% children and 15% adults in the CIBMTR
cohort received stem cells derived from bone marrow
only, whereas 94% children and 96% adults received
both bone marrow and peripheral blood in the Dao-
Pei cohort.
Outcomes for All Patients
Table 2 shows the univariate analyses. Despite the
differences in clinical characteristics between the
CIBMTR and Dao-Pei cohorts, within each cohort,
there were no statistically significant differences in en-
graftment, aGVHD and cGVHD, TRM, relapse,
LFS, and OS between adults and children. Table 3
summarizes the clinical variables considered in the
multivariate analyses. Table 4 presents the multivari-
ate analysis results for the CIBMTR and the Dao-Pei
cohort separately, which are summarized below.
CIBMTR Cohort
In the multivariate analysis in the CIBMTR co-
hort, a significant interaction between age and ex
vivo TCD for OS and DFS was detected so 4 sub-
groups (adult-no TCD, adult-TCD, child-no TCD,
and child-TCD) were compared (Table 4). No other
interactions were present. When ex vivo TCD was
used, there were statistically significant differences be-
tween the outcomes of adults and children. Adult-
TCD was associated with a higher risk of TRM (RR
2.71, 95% confidence interval [CI] 1.29-5.69, P 5
.008) and lower OS (relative risk [RR] 1.75, 95% CI
1.08-2.84, P 5 .023) than child-TCD. When ex vivo
TCD was not employed, there was a lower risk of re-
lapse in adult–no TCD compared with child–no
TCD (RR 0.24, 95% CI 0.07-0.80, P 5 .020) and
a suggestion of a higher LFS (RR 0.44, 95% CI
0.19-1.04, P 5 .060) and OS (RR 0.46, 95% CI 0.20-
1.02, P5 .056), which were not statistically significant
according to the P 5 .05 cutoff. There was no differ-
ence in TRM. Among all patients, advanced disease
was associated with higher TRM, higher relapse, and
lower LFS and OS. Transplantation more than 12
months from diagnosis was associated with higher
TRM, whereas use of ATGwas associated with a lower
relapse rate.
Influence of TCD and No-TCD in CIBMTR
Cohort
Given these results, we performed a post hoc com-
parison of transplant outcomes according to TCD sta-
tus. Adult-TCD had a higher cumulative incidence of
TRM (RR 3.18, 95% CI 1.38-7.37, P 5 .007) and re-
lapse (RR 4.28, 95% CI 1.52-12.05; P 5 .006) as well
Table 2. Univariate Analysis
Outcome event n
CIBMTR Cohort
P Value n
Dao-Pei Cohort
P Value
Children
n
Adults Children
n
Adults
Prob (95% CI) Prob (95% CI) Prob (95% CI) Prob (95% CI)
ANC >0.5  109/L 50 87
28 days 86 (75-94)% 77 (68-85)% .172 68 99 (94-100)% 113 97 (94-99)% .549
Platelet >20  109/L 50 84 68 113
60 days 74 (61-85)% 60 (49-70)% .076 85 (76-93)% 91 (85-96)% .244
100 days 76 (63-87)% 62 (51-72)% .077 85 (76-93)% 93 (88-97)% .119
Acute GVHD 2-4 50 85 68 113
100 days 24 (13-37)% 18 (10-27)% .402 47 (35-59)% 41 (32-50)% .403
Acute GVHD 3-4 50 85 68 113
100 days 10 (3-20)% 11 (5-18)% .912 19 (11-29)% 15 (9-22)% .485
Chronic GVHD 50 87 68
1 year 17 (8-30)% 18 (10-28)% .874 51 (39-63)% 38 (29-48)% .101
TRM 48 85 68 113
1 year 28 (16-42)% 39 (28-49)% .229 21 (12-31)% 26 (18-34)% .428
3 years 31 (18-44)% 42 (31-53)% .205 31 (21-42)% 32 (24-41)% .871
Relapse 48 85 68 113
1 year 47 (33-61)% 33 (23-44)% .125 9 (3-17)% 14 (8-21)% .262
3 years 49 (35-64)% 35 (25-46)% .108 16 (8-26)% 17 (11-24)% .909
LFS 48 85 68 113
1 year 25 (13-38)% 28 (19-39)% .656 71 (59-81)% 60 (51-69)% .148
3 years 20 (10-33)% 24 (15-34)% .645 53 (41-65)% 51 (42-60)% .814
Overall survival 50 87 68 113
1 year 34 (21-48)% 37 (27-48)% .720 75 (64-84)% 66 (57-75)% .210
3 years 19 (8-32)% 24 (15-35)% .473 54 (43-66)% 53 (44-62)% .836
ANC indicates absolute neutrophil count; GVHD, graft-versus-host disease; TRM, treatment-related mortality; LFS, leukemia-free survival; CI, confi-
dence interval.
Table 3. Variables Tested in the Multivariate Analysis
Main effect:
Children* versus adults
Patient-related variables:
Age at transplant, years in decades
Gender of patient: female versus male*
Lansky/Karnofsky performance score at transplant: <90 versus $90* versus unknown
Biol Blood Marrow Transplant 17:1205-1213, 2011 1209Haploidentical Transplant in Children and Adultsas higher rates of graft failure (RR 3.25, 95% CI 1.71-
6.18, P\ .001) and increased mortality (RR 5 3.81,
95% CI 2.01-7.22, P\ .001) compared to adult–no
TCD. Among the non-TCD patients, adult–no
TCD had a lower relapse rate (RR 0.24, P 5 .02)
and almost had better survival (RR 0.46, P 5 .056)
and better LFS (RR 0.44, P 5 .06) than children. For
children, there was no difference in outcomes between
TCD and no-TCD (Figure 1).
Dao-Pei Cohort
In the Dao-Pei cohort, we observed no differences
between adults and children in TRM, relapse, LFS, or
OS (Figure 2). Karnofsky score $90 was associated
with lower TRM, lower relapse, and higher LFS and
OS. Disease type also predicted relapse. ALLwas asso-
ciated with higher relapse rate than other diagnoses.Disease-related variables:
Disease: acute myeloid leukemia* versus acute lymphoid leukemia versus chronic
myeloid leukemia versus myelodysplastic syndrome
Disease stage: early* versus intermediate versus advanced
Time from diagnosis to transplant, month: <12 months* versus $12 months
Transplant-related variables
Stem cell source: BM* versus BM ± PB
T cell depletion ex vivo: No* versus yes (CIBMTR cohort only)
Use of ATG in conditioning regimen or GVHD prophylaxis: No* versus yes (in CIBMTR
cohort only)
Donor relationship: sibling* versus parent versus child versus other relatives
HLA matching: 3/6* versus 4/6 (in Dao-Pei cohort only)
Donor/recipient gender match: female/male* versus female/female versus
male/female versus male/male
ABO match: matched* versus minor mismatch versus major mismatch
versus bidirectional
Donor age, by decades: <30* versus 31-40 versus $41
Year of transplant: 2000-2003* versus 2004-2005
BM indicates bone marrow; PB, peripheral blood; ATG, antithymocyte
globulin; GVHD, graft-versus-host disease.
*Baseline.DISCUSSION
Our study confirms that haploidentical transplan-
tation for hematologic malignancies in adults and chil-
dren using myeloablative conditioning and standard
GVHD prophylaxis is a reasonable treatment option,
although we did not find that outcomes in children
were superior to those seen in adults among the
Dao-Pei cohort or within the non-TCD subset of
the CIBMTR. Only among the ex vivo TCD recipi-
ents reported to the CIBMTR did we see better out-
comes in the children compared to the adults. In this
group, children had lower rates of TRM and trends to-
ward better LFS and OS.The apparent better outcomes seen in the Dao-Pei
cohort overall compared to the CIBMTR cohort could
be because of inherent differences in the patient popu-
lations, differences in clinical management, or the fact
that the Dao-Pei data were all derived from a single
center, compared to the CIBMTR cohort where
25 centers contributed data for children and 32
(Table 1) centers provided data for adults. All patients
in the Dao-Pei cohort received in vivo ATG based on
Table 4. Age Effect in Patients Undergoing Related HLA-Mismatched/Haploidentical Transplantation
CIBMTR Cohort n RR(95% CI) P
TRM: .120*
Adults versus children with no-TCD 30/13 0.80 (0.21-3.03) .744
Adults versus children with TCD 55/35 2.71 (1.29-5.69) .008
Other significant covariates:
Advanced versus early/intermediate disease 65/68 1.89 (1.04-3.41) .036
Time from diagnosis to transplant: >12 versus #12 months 47/86 1.78 (1.00-3.18) .051
Relapse: .070*
Adults versus children with no-TCD 30/13 0.24 (0.07-0.80) .020
Adults versus children with TCD 55/35 0.86 (0.44-1.68) .650
Other significant covariates:
Advanced versus early/intermediate disease 65/68 5.09 (2.65-9.80) <.001
Use of ATG: yes versus no 92/41 0.37 (0.20-0.68) .002
LFS: .014*
Adults versus children with no-TCD 30/13 0.44 (0.19-1.04) .060
Adults versus children with TCD 55/35 1.52 (0.94-2.45) .087
Other significant covariates:
Advanced versus early/intermediate disease 65/68 2.76 (1.81-4.20) <.001
OS: .006*
Adults versus children with no-TCD 32/15 0.46 (0.20-1.02) .056
Adults versus children with TCD 55/35 1.75 (1.08-2.84) .023
Other significant covariates:
Advanced versus early/intermediate disease 68/69 2.53 (1.67-3.84) <.001
Dao-Pei Cohort n RR(95% CI) P
TRM:
Adults versus children 113/68 0.98 (0.58-1.68) .950
Other significant covariates:
Karnofsky Score: $90 versus < 90 128/53 0.42 (0.25-0.72) .002
Relapse:
Adults versus children 113/68 1.36 (0.63-2.96) .437
Other significant covariates: 128/53 0.27 (0.13-0.55) <.001
Karnofsky score: $90 versus <90
Disease: acute myeloid leukemia 56 1.00 .019†
Acute lymphoid leukemia 64 2.78 (1.14-6.75) .024
Chronic myeloid leukemia 50 0.66 (0.19-2.24) .500
Myelodysplastic syndrome 11 0.86 (0.17-4.21) .850
LFS:
Adults versus children 113/68 1.26 (0.78-2.01) .344
Other significant covariates:
Karnofsky score: $90 versus <90 128/53 0.36 (0.23-0.55) <.001
Disease: acute myeloid leukemia 56 1.00 .038†
Acute lymphoid leukemia 64 1.54 (0.93-2.55) .095
Chronic myeloid leukemia 50 0.70 (0.38-1.28) .245
Myelodysplastic syndrome 11 0.64 (0.24-1.70) .373
Time from diagnosis to transplant: >12 versus #12 months 43/138 1.60 (0.99-2.59) .055
OS:
Adults versus children 113/68 0.93 (0.59-1.45) .741
Other significant covariates:
Karnofsky Score: $90 versus <90 128/53 0.35 (0.22-0.54) <.001
TCD indicates T cell depletion ex vivo; TRM, treatment-related mortality; LFS, leukemia-free survival; OS, overall survival; RR, relative risk; CI,
confidence interval.
*Test interaction; †3 d.f. test.
1210 Biol Blood Marrow Transplant 17:1205-1213, 2011L. Dong et al.the belief that ATG reduces the incidence of GVHD
without damaging the hematopoietic cell precursor
population or impeding immune reconstitution. In
108 patients with parent donors (see Table 1), mothers
were used as the donor in 76 (70%) pairs, because this
combination has been associated with improved out-
comes, based on presumed maternal-fetal microchi-
merism and resulting tolerance [20,21].
Children in the CIBMTR cohort who received ex
vivo TCD had better outcomes than similarly treated
adults, adjusting for other clinical characteristics.
One contributing factor may be that children were
more likely to achieve ‘‘megadose’’ CD341 cells than
adults because of their lower weight, and the CD341
dose may be more important in the TCD setting
[22].Modern haploidentical transplant protocols usinghigh doses of CD341 purified cells and myeloablative
conditioning report sustained engraftment rates
of over 90%. In addition, full donor chimerism
and low rates of aGVHD and cGVHD are seen
[23-26]. In adults, a relatively lower CD341cell dose
per kg may be a major cause of unstable chimerism
and incomplete immunologic reconstitution after
transplantation, although we did not see statistically
significant differences in engraftment or recurrent
malignancy.
Post hoc analysis of the CIBMTR cohort sug-
gested that adults should not receive a TCD graft, be-
cause TRM and relapse were higher, and LFS and
survival lower in adults with TCD compared to adults
who did not receive TCD, adjusted for other clinical
features. However, we consider this a hypothesis-
Figure 1. (A) Cumulative incidence of TRM, (B) cumulative incidence of relapse, (C) adjusted probability of LFS, and (D) adjusted probability of OS
(adults versus children with no TCD/with TCD) from CIBMTR cohort. TED indicates T cell depletion ex vivo; TRM, treatment-related mortality;
LFS, leukemia-free survival; OS, overall survival.
Biol Blood Marrow Transplant 17:1205-1213, 2011 1211Haploidentical Transplant in Children and Adultsgenerating analysis that requires additional study, ide-
ally in a randomized trial.
Because virtually almost every patient has a haploi-
dentical family member donor available, there has
been great interest in developing transplant ap-
proaches that permit this degree of HLA disparity dur-
ing transplantation. Only approximately 50% of
patients with an indication for unrelated donor HCT
may ultimately receive the intended allograft. ThatFigure 2. (A) Cumulative incidence of TRM, (B) cumulative incidence of rela
(adults versus children) from the Dao-Pei cohort. TRM indicates treatment-repercentage may be even lower for patients with
a non-White background [27]. Our study suggests
that in most settings, the outcomes of adults and chil-
dren appear comparable so age should not automati-
cally be considered an adverse prognostic factor.
Rather, other traditional clinical factors such as disease
stage, disease type, time from diagnosis to HCT, and
Karnofsky performance status appear to be much
stronger predictors of transplantation success.pse, (C) adjusted probability of LFS, and (D) adjusted probability of OS
lated mortality; LFS, leukemia-free survival; OS, overall survival.
1212 Biol Blood Marrow Transplant 17:1205-1213, 2011L. Dong et al.Research to help identify the optimal combinations of
conditioning agents and GVHD approaches and to
select the optimal donors may continue to improve
outcomes.
Treatment approaches to haploidentical trans-
plantation vary greatly and continue to evolve. These
include modifications to donor selection such as con-
sideration of fetomaternal michrochimerism [28-30],
noninherited maternal antigens (NIMA) [20,21,31],
or killer immunoglobulin-like receptor (KIR) status
[32,33], as well as use of nonmyeloablative con-
ditioning regimens [1,34-36] or alteration of the
GVHD prophylaxis approach with posttransplant
cyclophosphamide [37]. Studies to date show 2-year
survival rates of 50 6 20% [38].
Our study has a number of limitations. First, the
overall study numbers are relatively low although
they do represent the largest report of haploidentical
transplantation using traditional GVHD prophylaxis
approaches. The small subsets limit the power to de-
tect differences, although evaluation of the figures sug-
gests that this was not the reason for the failure to find
differences. Second, although the original intention
was to combine the CIBMTR and Dao-Pei cohorts,
the inherent differences in patient characteristics,
transplant approaches and outcomes did not make
this possible. We are left without clear understanding
of why the outcomes differed so greatly. Finally, de-
spite the readily available donor source, haploidentical
transplantation is still relatively uncommon, and ap-
proaches are rapidly evolving. Further study and larger
numbers of more homogenously treated patients
would enhance our understanding of clinical and
transplant factors associated with better outcomes.ACKNOWLEDGMENTS
Financial disclosure: The CIBMTR is supported by
Public Health Service Grant/Cooperative Agreement
U24-CA76518 from the National Cancer Institute
(NCI), the National Heart, Lung and Blood Institute
(NHLBI), and theNational Institute of Allergy and In-
fectious Diseases (NIAID); a Grant/Cooperative
Agreement 5U01HL069294 from NHLBI and NCI;
a contract HHSH234200637015C with Health Re-
sources and Services Administration (HRSA/DHHS);
Grants N00014-06-1-0704 and N00014-08-1-0058
from the Office of Naval Research; and grants from
AABB; Aetna; American Society for Blood andMarrow
Transplantation; Amgen, Inc.; anonymous donation to
the Medical College of Wisconsin; Astellas Pharma
US, Inc.; Baxter International, Inc.; Bayer HealthCare
Pharmaceuticals; Be the Match Foundation; Biogen
IDEC; BioMarin Pharmaceutical, Inc.; Biovitrum
AB; BloodCenter of Wisconsin; Blue Cross and Blue
Shield Association; Bone Marrow Foundation; Cana-
dian Blood and Marrow Transplant Group; Cari-dianBCT; Celgene Corporation; CellGenix, GmbH;
Centers for Disease Control and Prevention; Chil-
dren’s Leukemia Research Association; ClinImmune
Labs; CTI Clinical Trial and Consulting Services;
Cubist Pharmaceuticals; Cylex Inc.; CytoTherm;
DOR BioPharma, Inc.; Dynal Biotech, an Invitrogen
Company; Eisai, Inc.; Enzon Pharmaceuticals, Inc.;
European Group for Blood and Marrow Transplanta-
tion; Gamida Cell, Ltd.; GE Healthcare; Genentech,
Inc.; Genzyme Corporation; Histogenetics, Inc.;
HKS Medical Information Systems; Hospira, Inc.; In-
fectious Diseases Society of America; Kiadis Pharma;
Kirin Brewery Co., Ltd.; The Leukemia&Lymphoma
Society; Merck & Company; The Medical College of
Wisconsin; MGI Pharma, Inc.; Michigan Community
Blood Centers; Millennium Pharmaceuticals, Inc.;
Miller Pharmacal Group; Milliman USA, Inc.; Milte-
nyi Biotec, Inc.; National Marrow Donor Program;
Nature Publishing Group; New York Blood Center;
Novartis Oncology; OncologyNursing Society; Osiris
Therapeutics, Inc.; Otsuka America Pharmaceutical,
Inc.; Pall Life Sciences; PDL BioPharma, Inc; Pfizer
Inc.; Pharmion Corporation; Saladax Biomedical, Inc.;
Schering Corporation; Society for Healthcare Epide-
miology of America; StemCyte, Inc.; StemSoft
Software, Inc.; Sysmex America, Inc.; Teva Pharma-
ceutical Industries; THERAKOS, Inc.; Thermogene-
sis Corporation; Vidacare Corporation; Vion
Pharmaceuticals, Inc.; ViraCor Laboratories; Viro-
Pharma, Inc.; andWellpoint, Inc. The views expressed
in this article do not reflect the official policy or posi-
tion of the National Institutes of Health, the Depart-
ment of the Navy, the Department of Defense, or any
other agency of the U.S. Government.AUTHORSHIP STATMENT
Contributions: L.J. Dong, D.P. Lu, and T. Wu,
designed and supervised the study (IB06-04,
CIBMTR). L.J. Dong and T. Wu compiled clinical
data. F. Kan, M.J. Zhang, and L.J. Dong performed
the statistical analysis. L.J. Dong, M.J. Zhang and
S.J. Lee drafted the manuscript. All authors provided
critical feedback and approved the final manuscript.REFERENCES
1. Van Rood JJ, Loberiza FR Jr., Zhang MJ, et al. Effect of toler-
ance to noninherited maternal antigens on the occurrence of
graft-versus-host disease after bone marrow transplantation
from a parent or an HLA-haploidentical sibling. Blood. 2002;
99:1572-1577.
2. Fischer A, Durandy A, de Villartay JP, et al. HLA-haploidentical
bone marrow transplantation for severe combined immunodefi-
ciency using E Rosette fractionation and cyclosporine. Blood.
1986;67:444-449.
3. Lu DP, Dong L, Wu T, et al. Conditioning including antithy-
mocyte globulin followed by un-manipulated HLA-
mismatched/haploidentical blood and marrow transplantation
Biol Blood Marrow Transplant 17:1205-1213, 2011 1213Haploidentical Transplant in Children and Adultscan achieve comparable outcomes to HLA-identical sibling
transplantation. Blood. 2006;107:3065-3073.
4. Chen XH, Zhang C, Zhang X, et al. Role of antithymocyte glob-
ulin and granulocyte-colony stimulating factor-mobilized bone
marrow in allogeneic transplantation for patients with hemato-
logic malignancies. Biol Blood Marrow Transplant. 2009;15:
266-273.
5. Guo M, Sun Z, Sun QY, et al. A modified haploidentical non-
myeloablative transplantation without T cell depletion for
high-risk acute leukemia: successful engraftment and mild
GVHD. Biol Blood Marrow Transplant. 2009;15:930-937.
6. Spitzer TR. Haploidentical Stem Cell Transplantation: The Always
Present but Overlooked Donor. Thomas R. Hematology Am Soc
Hematol Educ Program; 2005:390-395.
7. Kolb HJ. Graft-versus-leukemia effects of transplantation and
donor lymphocytes. Blood. 2008;112:4371-4383.
8. Satake A, Inoue T, Kubo S, et al. Separation of antileukemic ef-
fects from graft-versus-host disease inMHC-haploidentical mu-
rine bone marrow transplantation: participation of host immune
cells. Int J Hematol. 2010;91:485-497.
9. Symons HJ, Leffell MS, Rossiter ND, et al. Improved survival
with inhibitory killer immunoglobulin receptor (KIR) gene mis-
matches and KIR haplotype B donors after nonmyeloablative,
HLA-haploidentical bone marrow transplantation. Biol Blood
Marrow Transplant. 2010;16:533-542.
10. Ciceri F, Labopin M, Aversa F, et al. A survey of fully haploi-
dentical hematopoietic stem cell transplantation in adults
with high-risk acute leukemia: a risk factor analysis of outcomes
for patients in remission at transplantation. Blood. 2008;112:
3574-3581.
11. Aversa F. Haploidentical haematopoietic stem cell trans-
plantation for acute leukaemia in adults: experience in Europe
and theUnitedStates.BoneMarrowTransplant. 2008;41:473-481.
12. Pende D, Marcenaro S, Falco M, et al. Anti-leukemia activity of
alloreactive NK cells in KIR ligand-mismatched haploidentical
HSCT for pediatric patients: evaluation of the functional role
of activating KIR and redefinition of inhibitory KIR specificity.
Blood. 2009;113:3119-3129.
13. Wang HX, Yan HM, Duan LN, et al. Haploidentical hemato-
poietic stem cell transplantation in child hematologic malignan-
cies with G-CSF-mobilized marrow grafts without T-cell
depletion: a single-center report of 45 cases. Pediatr Hematol
Oncol. 2009;26:119-128.
14. Woolfrey AE,GooleyTA, Sievers EL, et al. Bonemarrow trans-
plantation for children less than 2 years of age with acute mye-
logenous leukemia or myelodysplastic syndrome. Blood. 1998;
92:3546-3556.
15. Gonzalez-Vicent M, Perez A, Abad L, et al. Graft manipulation
and reduced-intensity conditioning for allogeneic hematopoi-
etic stem cell transplantation from mismatched unrelated and
mismatched/haploidentical related donors in pediatric leukemia
patients. J Pediatr Hematol Oncol. 2010;32:e85-e90.
16. Dong L, Wu T, Zhang MJ, Gao ZY, Lu DP. CD31 cell dose
and disease status are important factors determining clinical out-
comes in patients undergoing unmanipulated haploidentical
blood and marrow transplantation after conditioning including
antithymocyte globulin. Biol Blood Marrow Transplant. 2007;13:
1515-1524.
17. Li-Ru Wang, Lu-Jia Dong, Mei-Jie Zhang, Dao-Pei Lu. The
impact of human herpesvirus 6b reactivation on early complica-
tions following allogeneic hematopoietic stem cell transplanta-
tion. Biol Blood Marrow Transplant. 2006;12:1031-1037.
18. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations
of graft-versus-host disease in human recipients of marrow
from HL-A-matched sibling donors. Transplantation. 1974;18:
295-304.
19. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-
versus-host syndrome in man. A long-term clinicopathologic
study of 20 Seattle patients. Am J Med. 1980;69:204-217.20. Van Rood JJ. You will never forget your mother! Blood. 2006;
107:7.
21. Cornelissen JJ. Mother and child reunion. Blood. 2008;112:
2604-2605.
22. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of
T-cell-depleted haploidentical ‘‘3-loci’’ incompatible trans-
plants in leukemia patients by addition of recombinant human
granulocyte colony-stimulating factor-mobilized peripheral
blood progenitor cells to bone marrow inoculum. Blood. 1994;
84:3948-3955.
23. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk
acute leukemia with T-cell-depleted stem cells from related do-
nors with 1 fully mismatched HLA haplotype. N Engl J Med.
1998;339(17):1186-1193.
24. Handgretinger R, Lang P. The history and future prospective of
haplo-identical stem cell transplantation. Cytotherapy. 2008;10:
443-451.
25. Kang Y, Chao NJ, Aversa F. Unmanipulated or CD34 selected
haplotype mismatched transplants. Curr Opin Hematol. 2008;
15:561-567.
26. Reisner Y,MartelliMF. From ‘‘megadose’’ haploidentical hema-
topoietic stem cell transplants in acute leukemia to tolerance in-
duction inorgan transplantation.BloodCellsMolDis. 2008;40:1-7.
27. HeemskerkMB, vanWalraven SM, Cornelissen JJ, et al. How to
improve the search for an unrelated haematopoietic stemcell do-
nor: faster is better thanmore. BoneMarrow Transplant. 2005;35:
645-652.
28. Stern M, Ruggeri L, Mancusi A, et al. Survival after T cell de-
pleted haploidentical stem cell transplantation is improved using
the mother as donor. Blood. 2008;112:2990-2995.
29. Shimazaki C, Ochiai N, Uchida R, et al. Non-T-cell–depleted
HLAhaploidentical stem cell transplantation in advanced hema-
tologic malignancies based on the feto-maternal michrochimer-
ism. Blood. 2003;101:3334-3336.
30. Yoshihara T,Morimoto A, Inukai T, et al. Non-T-cell-depleted
HLA haploidentical stem cell transplantation based on feto-
maternal microchimerism in pediatric patients with advanced
malignancies. Bone Marrow Transplant. 2004;34:373-375.
31. Ichinohe T, Uchiyama T, Shimazaki C, et al. Feasibility of
HLA-haploidentical hematopoietic stem cell transplantation
between non-inherited maternal antigen (NIMA)-mismatched
family members linked with long-term fetomaternal microchi-
merism. Blood. 2004;104:3821-3828.
32. Stern M, de Angelis C, Urbani E, et al. Natural killer-cell KIR
repertoire reconstitution after haploidentical SCT. BoneMarrow
Transplant. 2010;45:1607-1610.
33. Symons HJ, Leffell MS, Rossiter ND, et al. Improved survival
with inhibitory killer immunoglobulin receptor (KIR) gene mis-
matches and KIR haplotype B donors after nonmyeloablative,
HLA-haploidentical bone marrow transplantation. Biol Blood
Marrow Transplant. 2010;16:533-542.
34. Rizzieri DA, Koh LP, Long GD, et al. Partially matched, non-
myeloablative allogeneic transplantation: clinical outcomes
and immune reconstitution. J Clin Oncol. 2007;25:690-697.
35. Koh LP, Chao NJ. Non-myeloablative allogeneic hematopoi-
etic stem cell transplant using mismatched/haploidentical do-
nors: a review. Blood Cells Mol Dis. 2008;40:20-24.
36. Ikegame K, KawakamiM, Yamagami T, et al. HLA-haploident-
ical nonmyeloablative stem cell transplantation: induction to
tolerance without passing through mixed chimaerism. Clin Lab
Haematol. 2005;27:139-141.
37. Luznik L, O’Donnell PV, Symons HJ, et al. HLA-haploidenti-
cal bone marrow transplantation for hematologic malignancies
using nonmyeloablative conditioning and high-dose, posttrans-
plantation cyclophosphamide. Biol Blood Marrow Transplant.
2008;14:641-650.
38. SymonsHJ, Fuchs EJ.Hematopoietic SCT frompartiallyHLA-
mismatched (HLA-haploidentical) related donors. Bone Marrow
Transplant. 2008;42:365-377.
